Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBS | P35520 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.50 |
| ▸ | EP300 | Q09472 | 1/20 | 0.50 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.50 |
| ▸ | KAT5 | Q92993 | 1/20 | 0.50 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18983162 | 1.00 | CBS (0.54) | CBSOPRM1OPRD1OPRK1EP300 | |
| SCHEMBL16984607 | 1.00 | CBS (0.54) | CBSOPRM1OPRD1OPRK1EP300 | |
| Cardanol SCHEMBL29350748 | 0.98 | CBS (0.53) | CBSOPRM1OPRD1OPRK1EP300 | |
| Cardanol SCHEMBL2687568 | 0.98 | CBS (0.53) | CBSOPRM1OPRD1OPRK1EP300 | |
| Cardanol SCHEMBL4173456 | 0.98 | CBS (0.53) | CBSOPRM1OPRD1OPRK1EP300 | |
| Cardanol SCHEMBL29973669 | 0.98 | CBS (0.53) | CBSOPRM1OPRD1OPRK1EP300 | |
| Cardanol SCHEMBL2290369 | 0.98 | CBS (0.53) | CBSOPRM1OPRD1OPRK1EP300 | |
| SCHEMBL18924990 | 0.94 | EP300 (0.49) | CBSOPRM1OPRD1OPRK1EP300 | |
| SCHEMBL22986526 | 0.92 | CBS (0.56) | CBSOPRM1OPRD1OPRK1MGLL | |
| SCHEMBL30920963 | 0.91 | CBS (0.51) | CBSOPRM1OPRD1OPRK1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3099654-B1 | SYNTHETIC METHOD | UNIV COURT UNIV ST ANDREWS (GB) | 2018-05-09 | — | — | EP | disclosed |
| US-9908826-B2 | Synthetic method | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2018-03-06 | — | — | US | disclosed |
| US-20170174608-A1 | Synthetic Method | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2017-06-22 | — | — | US | disclosed |
| EP-3099654-A1 | SYNTHETIC METHOD | University Court of The University of St Andrews (GB) | 2016-12-07 | — | — | EP | disclosed |
| WO-2015114323-A1 | SYNTHETIC METHOD | UNIVERSITY COURT OF THE UNIVERSITY OF ST ANDREWS (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170174608-A1 | Synthetic Method | SQLE, FDFT1, CYP51A1 | CBS 97/4885OPRM1 1566/4885OPRD1 1481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.